Giada Grelli

MD, Medical Oncology Resident at @Unipisa 🇮🇹| Fellow at @HopitalPompidou 🇫🇷

[Giada Grelli @GiadaGrelli_]

💥 R(AS)evolutiON !

@RevMedicines

[Paolo Ciracì @p_ciracimd]

🚨KRAS is no longer undruggable.

DaraxonRASib shows OS 13.2 vs 6.7 months (HR 0.40, P<0.001) in pancreatic cancer.

👉 Press release: https://t.co/U5jinDgjom

@OncoAlert

[Federico Nichetti @fedenichetti]

Just out in @myESMO GO: our PANCAKE study🥞

🟣Diabetic patients with PDAC ➡️ longer OS with GemNabP, not FOLFIRINOX

This work is a testament to a growing community of young 🇮🇹researchers dedicated to #PDAC with rigorous science
@oncodaily @OncoDailyGI https://t.co/AuJ5dV53Eb

[Tania Fleitas Kanonnikoff @tfleitask]

Day 1 at the ESMO Gastric Cancer Preceptorship 🇪🇸
Kicking off with powerful insights and great company. Grateful to @myESMO for the great organisation!

#ESMO #GastricCancer #Oncology #Day1 #Madrid

[andrea casadei gardini @casadei_gardini]

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population https://t.co/jxCcdRwyzO

[Arndt Vogel @ArndtVogel]

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer
@NEJM
https://t.co/b3W2cVQE9F
👉Trastuzumab deruxtecan significantly improved overall survival than ramucirumab paclitaxel
🧐Looking forward to the 1st line trials
@myESMO

[Arndt Vogel @ArndtVogel]

Durvalumab + FLOT in resectable GC/GEJ cancer
#ASCO25 Plenary session
🔎MATTERHORN
👉mEFS n.r. vs 32.8, HR 0.71
👉mDFS n.r. vs 39.8 mo
👉OS n.r. in both arms, HR 0.78, not (yet) significant
👉pCR 19 vs 7%
🧐 Finally, ICI arrived in the peri-operative setting
@myESMO

[Giada Grelli @GiadaGrelli_]

So proud of my talented friend @p_ciracimd who has just presented the phase 1 TriComB study! 🚀
#AIOM24

[Giada Grelli @GiadaGrelli_]

Can we rely on peritoneal specimens for PD-L1 assessment? 🧐

The spatial and temporal heterogeneity of PD-L1 expression in mGEA is a critical issue!
Our paper now online on ESMO Gastrointestinal Oncology 👇🏼
https://t.co/Oza8ys8pgm

[andrea casadei gardini @casadei_gardini]

Our last paper…fantastic international collaboration
-CisGem durvalumab in BTC patients 
-666 patients: median OS of 15.1 months and median PFS of 8.2 months
-The results confirmed the results achieved in the TOPAZ-1 trial
https://t.co/QmOW3dIN2u

[Paolo Ciracì @p_ciracimd]

#ESMOGI24 has been incredible!
@myESMO

[Giada Grelli @GiadaGrelli_]

A priviledge to be part of this team! 🚀

[Chiara Cremolini @ChiaraCrem1]

#ESMOGI24 is coming to an end… an excellent first time! Science, networking and fun… highly recommendable! Now ready to bring energy and motivation to our daily life and patients. ⁦@VStudiale⁩ ⁦⁦@p_ciracimd⁩ ⁦@myESMO⁩ #ESMOAmbassadors

[Giada Grelli @GiadaGrelli_]

What a beautiful session on oesophago-gastric cancer this morning at #ESMOGI24! Totally inspiring to listen to @FlorianLordick and @LizzySmyth1!
@myESMO

[Giada Grelli @GiadaGrelli_]

So grateful and excited to have the opportunity to present at #ESMOGI24 our prospective study on the prognostic impact of mutKRAS cftDNA in BR and LA PDAC !
@myESMO

[Giada Grelli @GiadaGrelli_]

What an honour to hear Prof.@salahAlBatran talk about neoadjuvant treatment in GC !
#neoadjuvantpro #ESMOGI24
@myESMO

[Giada Grelli @GiadaGrelli_]

Oustanding presentation by @MyriamChalabi on IO for MMR CRC!
#ESMOGI24 @myESMO

[Giada Grelli @GiadaGrelli_]

The best way to start #ESMOGI24 with the keynote lecture on KRAS by Prof. Corcoran!
@myESMO

[Arndt Vogel @ArndtVogel]

🔥PLENARY Session #ASCO24🔥
Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus
🔎 ESOPEC phase III trial, 438 patients
👉R0 180 vs 171
👉pCR 17 vs 10%
👉mOS 66 vs 37 mo
👉3yr OS: 57.4 vs 50.7%
🧐FLOT improves OS compared to CROSS
@myESMO

[Giada Grelli @GiadaGrelli_]

What inspiring and educational lessons by @ian_tannock and @mattsydes !
Thanks to @AIOMtweet and @ASCO for this opportunity !
#clinicalresearchcourse

[AIOM @AIOMtweet]

Seconda edizione dell’ASCO-AIOM International Clinical Research Course: come sempre grande partecipazione ed entusiasmo.
#ASCO #AIOM @ASCO